Drug intelligence / Profile preview

Target W TPD

Development stage: Preclinical
Lead developer: Txinno Bioscience
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Oral

Overview

Target W TPD is an early-stage small-molecule targeted protein degrader (TPD) being developed by Txinno Bioscience. It is designed to selectively degrade an undisclosed protein, referred to as 'Target W,' which represents an intrinsic vulnerability in cancer cells. Unlike traditional inhibitors that block protein function, this TPD modality recruits the cellular ubiquitin-proteasome system to physically eliminate the target protein. The program is currently in the hit-to-lead phase of discovery and is part of Txinno's 'Targeted Therapy' pipeline focusing on intrinsic cancer vulnerabilities.

Beyond the preview

Go deeper on Target W TPD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Target W TPD.